乳腺癌免疫微环境类型的代谢特征及基于18F-FDG PET/CT影像组学的复合模型
回顾性分析207例乳腺癌患者211个原发灶,评估PD-L1与肿瘤浸润淋巴细胞定义的免疫微环境类型(TIMT)与18F-FDG PET/CT代谢参数的关系,并构建影像组学复合模型。TIMT-II在HER2+和三阴性乳腺癌中占比最高,TLR(P=0.03;OR:1.1)和Nottingham分级(P=0.006;OR:3.1)为TIMT-II的独立影响因素。复合模型对TIMT-II的预测在测试集AUC为0.86。
要点
- TIMT-II在HER2+乳腺癌中占64%(14/22),在三阴性乳腺癌中占63%(17/27)。
- 多数代谢参数在TIMT-II与TIMT-I或TIMT-II与TIMT-III间差异有统计学意义(P<0.05)。
- TLR(P=0.03;OR:1.1)和Nottingham分级(P=0.006;OR:3.1)为TIMT-II独立影响因素。
核心结论
- 不同TIMT间存在代谢差异,TIMT-II表现出明显升高的代谢特征。
- 基于影像组学的复合模型对TIMT-II具有较高预测效能,有潜力筛选ICIs应答者。
研究设计与样本
- 回顾性纳入2022年9月至2024年8月在本院行18F-FDG PET/CT检查的连续207例乳腺癌患者(211个原发灶)。
- 以PD-L1和肿瘤浸润淋巴细胞评估TIMT,分为TMIT-I(PD-L1-,TILs-)、TMIT-II(PD-L1+,TILs+)、TMIT-III(PD-L1-,TILs+)和TMIT-IV(PD-L1+,TILs-)。
- 分析SUVmax、TLR等代谢参数与TIMT的关系,并构建基于影像组学的复合预测模型。
主要发现
- TIMT-II在HER2+乳腺癌中占64%(14/22),在三阴性乳腺癌中占63%(17/27)。
- 多数代谢参数(如SUVmax和TLR)在TIMT-II与TIMT-I或TIMT-II与TIMT-III间差异有统计学意义(P<0.05)。
- TLR(P=0.03;OR:1.1)和Nottingham分级(P=0.006;OR:3.1)为TIMT-II的独立影响因素。
- 整合影像组学、代谢参数和临床病理数据的复合模型对TIMT-II的预测在测试集AUC为0.86。
关键数值与推荐
- TIMT-II独立影响因素:TLR(P=0.03;OR:1.1)和Nottingham分级(P=0.006;OR:3.1)。
- 复合模型对TIMT-II的预测效能:测试集AUC=0.86。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The intricateness of tumor immune microenvironment types (TIMTs) complicates identifying responders to immune checkpoint inhibitors (ICIs). Our purpose was to explore the metabolic characteristics of TIMTs in breast cancer using 18F-fluorodeoxyglucose (FDG) PET/CT and to establish radiomics-based predictive models for TIMTs. METHODS: Consecutive 207 breast cancer patients (211 primary lesions), who underwent 18F-FDG PET/CT examination from Sep 2022 to Aug 2024 in our hospital, were retrospectively reviewed. The programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) were evaluated for TIMTs: TMIT-I (PD-L1-, TILs-), TMIT-II (PD-L1+, TILs+), TMIT-III (PD-L1-, TILs+), and TMIT-IV (PD-L1+, TILs-). The relationship between metabolic parameters (such as maximum standardized uptake value (SUVmax) and tumor-to-liver SUV ratio (TLR)) and TIMTs was analyzed. Then composite predictive models based on radiomics were further developed. RESULTS: TIMT-II represented the highest proportion in HER2+ (14/22, 64%) and triple-negative (17/27, 63%) breast cancer. Most metabolic parameters (such as SUVmax and TLR) exhibited significant differences in TIMT-II vs. -I or TIMT-II vs. -III (P < 0.05). TLR (P = 0.03; OR: 1.1) and Nottingham grade (P = 0.006; OR: 3.1) were independent impact factors of TIMT-II. We further developed a composite model that integrated radiomics, metabolic parameter, and clinicopathological data, which demonstrated promising predictive efficacy for TIMT-II (AUC testing set = 0.86). CONCLUSION: Metabolic differences existed among different TIMTs, with TIMT-II exhibiting markedly elevated metabolic characteristics. The composite model based on radiomics demonstrated high predictive efficacy for TIMT-II and has the potential to screen ICIs responders.
引用
- Gao Y, Fu Z, Zhu X, et al. Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2025. PMID: 40325259. doi:10.1007/s00259-025-07306-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。